Skip to end of metadata
Go to start of metadata

2017 Publications

Title
AuthorsReferencePMID
Contributions of individual domains to function of the HIV-1 Rev response element.O'Carroll IPThappeta YFan LRamirez-Valdez EASmith SWang YXRein A.J Virol. 2017 Aug 16. pii: JVI.00746-17. doi: 10.1128/JVI.00746-17. [Epub ahead of print]28814520

Dissection of specific binding of HIV-1 Gag to the 'packaging signal' in viral RNA.

Comas-Garcia MDatta SABaker LVarma RGudla PRRein A.Elife. 2017 Jul 20;6. pii: e27055. doi: 10.7554/eLife.27055.28726630

Long Noncoding RNA PURPL Suppresses Basal p53 Levels and Promotes Tumorigenicity in Colorectal Cancer.

Li XLSubramanian MJones MFChaudhary RSingh DKZong XGryder BSindri SMo MSchetter AWen XParvathaneni SKazandjian DJenkins LMTang WElloumi FMartindale JLHuarte MZhu YRobles AIFrier SMRigo FCam MAmbs SSharma SHarris CCDasso MPrasanth KVLal A.Cell Rep. 2017 Sep5;20(10):2408-2423. doi: 10.1016/j.celrep.2017.08.041.28877474

Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to Matrin 3.

Chaudhary RGryder BWoods WSSubramanian MJones MFLi XLJenkins LMShabalina SAMo MDasso MYang YWakefield LMZhu YFrier SMMoriarity BSPrasanth KVPerez-Pinera PLal A.Elife. 2017 Jun 5;6. pii: e23244. doi: 10.7554/eLife.23244.28580901

Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma.

Dang HTakai AForgues MPomyen YMou HXue WRay DHa KCHMorris QDHughes TRWang XW.Cancer Cell. 2017Jul10;32(1):101-114.e8. doi: 10.1016/j.ccell.2017.06.002.28697339

The Functional Cycle of Rnt1p: Five Consecutive Steps of Double-Stranded RNA Processing by a Eukaryotic RNase III.

Song HFang XJin LShaw GXWang YXJi X.Structure. 2017 Feb 7;25(2):353-363. doi: 10.1016/j.str.2016.12.013. Epub 2017 Jan 19.28111020
Virus-Mediated Alterations in miRNA Factors and Degradation of Viral miRNAs by MCPIP1.  Happel CRamalingam DZiegelbauer JM.PLoS Biol. 2016 Nov 28;14(11):e2000998. doi: 10.1371/journal.pbio.2000998. eCollection 2016 Nov.27893764

Viral MicroRNAs Repress the Cholesterol Pathway, and 25-Hydroxycholesterol Inhibits Infection.

Serquiña AKPKambach DMSarker OZiegelbauer JM.MBio. 2017 Jul 11;8(4). pii: e00576-17. doi: 10.1128/mBio.00576-17.28698273
    
    

 

 

Other publications

pubmed: (caplen n[au] or fel...
NCBI: db=pubmed; Term=(Caplen N[AU] OR Felber B[AU] OR Franchini V[AU] OR Freed E[AU] OR Gottesman S[AU] OR Grewal S[AU] OR Harris C[AU] OR Hu W[AU] OR Huang J[AU] OR Hughes S[AU] OR Jessup J[AU] OR Ji X[AU] OR Johnson P[AU] OR Kashlev M[AU] OR KewalRamani V[AU] OR Khan J[AU] OR Kwong K[AU] OR Lal A[AU] OR Larson D[AU] OR LeGrice S[AU] OR Luo J[AU] OR Meltzer P[AU] OR Merlino G[AU] OR Mili V[AU] OR Misteli T[AU] OR Oberdoerffer S[AU] OR Pathak V[AU] OR Pavlakis G[AU] OR Rein A[AU] OR Ried T[AU] OR Shapiro B[AU] OR Singer D[AU] OR Staudt L[AU] OR Strathern J[AU] OR Wang Y[AU] OR Wang X[AU] OR Weissman A[AU] OR Young H[AU] OR Zhang Y[AU] OR Zheng ZM[AU] OR Zhurkin V[AU] OR Ziegelbauer J[AU]) AND (Bethesda OR Frederick)
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
Related Articles

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.

Lancet. 2017 Dec 04;:

Authors: Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, Berkowitz N, Mendoza F, Saunders JG, Novik L, Hendel CS, Holman LA, Gordon IJ, Cox JH, Edupuganti S, McArthur MA, Rouphael NG, Lyke KE, Cummings GE, Sitar S, Bailer RT, Foreman BM, Burgomaster K, Pelc RS, Gordon DN, DeMaso CR, Dowd KA, Laurencot C, Schwartz RM, Mascola JR, Graham BS, Pierson TC, Ledgerwood JE, Chen GL, VRC 319, VRC 320 study teams

Abstract
BACKGROUND: The Zika virus epidemic and associated congenital infections have prompted rapid vaccine development. We assessed two new DNA vaccines expressing premembrane and envelope Zika virus structural proteins.
METHODS: We did two phase 1, randomised, open-label trials involving healthy adult volunteers. The VRC 319 trial, done in three centres, assessed plasmid VRC5288 (Zika virus and Japanese encephalitis virus chimera), and the VRC 320, done in one centre, assessed plasmid VRC5283 (wild-type Zika virus). Eligible participants were aged 18-35 years in VRC19 and 18-50 years in VRC 320. Participants were randomly assigned 1:1 by a computer-generated randomisation schedule prepared by the study statistician. All participants received intramuscular injection of 4 mg vaccine. In VRC 319 participants were assigned to receive vaccinations via needle and syringe at 0 and 8 weeks, 0 and 12 weeks, 0, 4, and 8 weeks, or 0, 4, and 20 weeks. In VRC 320 participants were assigned to receive vaccinations at 0, 4, and 8 weeks via single-dose needle and syringe injection in one deltoid or split-dose needle and syringe or needle-free injection with the Stratis device (Pharmajet, Golden, CO, USA) in each deltoid. Both trials followed up volunteers for 24 months for the primary endpoint of safety, assessed as local and systemic reactogenicity in the 7 days after each vaccination and all adverse events in the 28 days after each vaccination. The secondary endpoint in both trials was immunogenicity 4 weeks after last vaccination. These trials are registered with ClinicalTrials.gov, numbers NCT02840487 and NCT02996461.
FINDINGS: VRC 319 enrolled 80 participants (20 in each group), and VRC 320 enrolled 45 participants (15 in each group). One participant in VRC 319 and two in VRC 320 withdrew after one dose of vaccine, but were included in the safety analyses. Both vaccines were safe and well tolerated. All local and systemic symptoms were mild to moderate. In both studies, pain and tenderness at the injection site was the most frequent local symptoms (37 [46%] of 80 participants in VRC 319 and 36 [80%] of 45 in VRC 320) and malaise and headache were the most frequent systemic symptoms (22 [27%] and 18 [22%], respectively, in VRC 319 and 17 [38%] and 15 [33%], respectively, in VRC 320). For VRC5283, 14 of 14 (100%) participants who received split-dose vaccinations by needle-free injection had detectable positive antibody responses, and the geometric mean titre of 304 was the highest across all groups in both trials.
INTERPRETATION: VRC5283 was well tolerated and has advanced to phase 2 efficacy testing.
FUNDING: Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

PMID: 29217376 [PubMed - as supplied by publisher]

Click here for all Pubmed records from members.

 

Last updated by Hooper, Laura (NIH/NCI) [E] on Sep 27, 2017